LIMX — what changed in the latest 10-Q
A section-by-section comparison of LIMX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-06-26 vs the prior 10-Q · 2025-11-19
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +10 | −9 | ~4 | 3 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 4 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +4 | −8 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-06-26
Limitless X Holdings Inc. is a Delaware corporation (the “Company,” “Limitless X,” “we,” or “us”) that, together with its subsidiaries, is building a diversified ecosystem across health, wellness, entertainment, and media-driven brand development. As of June 1, 2026, the Company conducts business th…
Through Limitless X, the Company operates a direct-to-consumer e-commerce platform offering dietary supplements and consumer packaged goods focused on cognitive support, energy, recovery, weight management, and general wellness. Its product portfolio includes the NZT-48 product line, OneShot Nootrop…
The Company’s entertainment and media operations are conducted through Limitless Films and Limitless Entertainment. Limitless Films is focused on the development, packaging, financing, and monetization of film and television content for domestic and international markets. In 2025, the Company was in…
BodyCor was established to consolidate and scale technology-driven wellness initiatives across the Limitless X ecosystem, including AI-assisted digital wellness tools designed to enhance the customer experience around existing and planned products. In January 2026, the Company acquired a 60% control…
The Company’s strategy is to combine consumer product sales, content production, live events, and technology-enabled platforms across its operating subsidiaries. Management believes this integrated approach may support customer acquisition efficiency and revenue diversification over time. While the …
Text removed vs the prior filing · source: 10-Q · 2025-11-19
On May 11, 2022, Bio Lab Naturals, Inc., a Delaware corporation (“Bio Lab”), entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Limitless X, Inc., a Nevada corporation (“LimitlessX”), and its 11 shareholders (the “LimitlessX Acquisition”). The parties completed and closed …
Other Income or Expense – During the three months ended September 30, 2025, the Company also recorded interest expense of approximately $0.2 and a gain on debt settlement of $1.7 million during the three months ended September 30, 2025 compared to $0.2 million of interest expense during the three mo…
For the Nine Months Ended September 30, 2025 Compared to the Nine Months Ended September 30, 2024:
Product Sales - Our product sales decreased by $2.2 million to $0.8 million for the nine months ended September 30, 2025 as compared to $3.0 million for the nine months ended September 30, 2024. In 2024, there was a shift in our marketing and selling strategies, including a change in performance mar…
Cost of Sales - Our cost of sales decreased from $0.8 million, or 26.4% of sales, in the nine months ended September 30, 2024 to $0.3 million, or 32.9% of sales, in the nine months ended September 30, 2025. As operations decreased during the period, so did our costs for freight, inventory, and other…
Other information
Text added vs the prior filing · source: 10-Q · 2026-06-26
During the quarter ended March 31, 2026, the Company did not file a Current Report on Form 8-K reporting the promissory notes and acquisition transactions described below. The Company is providing the following disclosure pursuant to Part II, Item 5(a) of Form 10-Q.
Effective January 1, 2026, the Company issued an unsecured promissory note to Jaspreet Mathur, the Company’s Chief Executive Officer, in the principal amount of $137,500 . Effective January 1, 2026, Limitless Entertainment Group Inc., a consolidated subsidiary of the Company “LIMX Entertainment”), i…
Effective January 1, 2026, the Company acquired the remaining 80% ownership interest in each of LIMX Entertainment and Limitless Films, Inc. from EM1 Capital, LLC, an entity wholly owned by Jaspreet Mathur, for $1.00 and other good and valuable consideration pursuant to the attached Transfer of Stoc…
Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange A…
Text removed vs the prior filing · source: 10-Q · 2025-11-19
Series D Dividend Waiver Agreements signed by Related Parties
Effective as of September 30, 2025, the Company entered into dividend waiver agreement (each, a “Dividend Waiver Agreement” and collectively, the “Dividend Waiver Agreements”) with all holders of the Company’s Series D Preferred Stock. The holders consisted of Jaspreet Mathur, the Company’s Chief Ex…
As of September 30, 2025, the Company had accrued and unpaid dividends on the Series D Preferred Stock in the amounts of $526,799 owed to Mr. Mathur, $4,658 owed to Emblaze, and $7,968 owed to EM1. Pursuant to the Waiver Agreements, each holder irrevocably waived its right to receive all accrued and…
Third Amendment to License Agreement and Royalty Payment Waiver
Limitless Performance Inc. (“LPI”), Smilz, Inc., Divatrim In.c (“Divatrim”) and Amarose, Inc (“Amarose”) (individually, each is a “Licensor” and collectively, the “Licensors”) are companies at least 50% owned by Mr. Jaspreet Mathur, the Company’s CEO. On December 1, 2021, the Company entered into li…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice